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FGF Inhibition Directs BMP4-Mediated Differentiation
of Human Embryonic Stem Cells to Syncytiotrophoblast
Smita Sudheer,1,2,* Raghu Bhushan,3 Beatrix Fauler,4 Hans Lehrach,1 and James Adjaye1,5
Bone morphogenetic protein (BMP) signaling is known to support differentiation of human embryonic stem cells
(hESCs) into mesoderm and extraembryonic lineages, whereas other signaling pathways can largely influence this
lineage specification. Here, we set out to reinvestigate the influence of ACTIVIN/NODAL and fibroblast growth
factor (FGF) pathways on the lineage choices made by hESCs during BMP4-driven differentiation. We show that
BMP activation, coupled with inhibition of both ACTIVIN/NODAL and FGF signaling, induces differentiation of
hESCs, specifically to bhCG hormone-secreting multinucleated syncytiotrophoblast and does not support induc-
tion of embryonic and extraembryonic lineages, extravillous trophoblast, and primitive endoderm. It has been
previously reported that FGF2 can switch BMP4-induced hESC differentiation outcome to mesendoderm. Here, we
show that FGF inhibition alone, or in combination with either ACTIVIN/NODAL inhibition or BMP activation,
supports hESC differentiation to hCG-secreting syncytiotrophoblast. We show that the inhibition of the FGF
pathway acts as a key in directing BMP4-mediated hESC differentiation to syncytiotrophoblast.
Introduction
Human embryonic stem cells (hESCs) originate from theinner cell mass of the blastocyst are self-renewing and
pluripotent with an innate ability to give rise to embryonic
and extraembryonic lineages [1,2]. ACTIVIN/NODAL and
fibroblast growth factor (FGF) signaling supports hESC self-
renewal [3–8]. They also form a subset of the key develop-
mental pathways, also including bone morphogenetic protein
(BMP) and WNT, instrumental in differentiation, which play
important roles in embryonic development [9,10].
In mouse, ACTIVIN/NODAL AND FGF signaling path-
ways are crucial for primitive streak (PS) formation, leading
to mesoderm and endoderm induction [11–15]. The lineage
specification into the initial cell types, epiblast, trophecto-
derm (TE), and primitive endoderm (PE) is dependent on the
FGF pathway [16–19]. Excessive FGF signaling is crucial for
PE formation [19] and is functional in switching the BMP4-
induced hESC differentiation to the mesendoderm [20].
FGF signaling can also promote or inhibit neuroectodermal
differentiation of ES cells in a context-dependent manner
[21–25]. Neuroectodermal differentiation can be induced by
inhibition of ACTIVIN/NODAL or BMP signaling or a
combination of both [5,7,26–28]. On the other hand, BMP
signaling can support differentiation of hESCs into multiple
lineages, including both embryonic [29–31] and extraem-
bryonic lineages [2,32], being essential for trophoblast
induction [33].
These independent findings emphasize the importance of
BMP, ACTIVIN/NODAL, and FGF signaling in a broad
range of cellular events, like self-renewal and differentiation,
which imply their influence on a contextual basis. Both
ACTIVIN/NODAL and FGF signaling can influence BMP-
mediated differentiation of hESCs [5,34,35]. BMP4- and
FGF2-induced signaling are known to cooperate in inducing
mesoderm and inhibiting endoderm differentiation of
hESCs, where the latter is functional in switching the BMP4-
induced hESC differentiation to mesendoderm [20,36].
Therefore, the importance of FGF signaling in mesendoderm
induction has been well deciphered. In this article, we show
that upon FGF inhibition, BMP4 directs hESC differentiation
to syncytiotrophoblast, preventing the other BMP4-driven
lineages such as mesendoderm and PE. In this study, we
reinvestigated the effect of these pathways on the outcome of
BMP4-driven differentiation of hESCs. Here, we show that
BMP activation, in combination with inhibition of both
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ACTIVIN/NODAL and FGF pathways, specifically drives
the differentiation of hESCs to syncytiotrophoblast, cir-
cumventing mesendoderm and PE induction. Furthermore,
we elucidate the crucial role of FGF inhibition in specifying
this differentiation process of hESCs to syncytiotrophoblast.
Materials and Methods
Cell culture
The experiments were carried out using the Human ES
lines H1 and H9 obtained from WiCell and cultured on
Matrigel-coated plates under defined conditions (N2B27)
[37]. The cells were passaged and maintained in an MEF-
conditioned medium [38] till they reach a confluency of
*40%–50%. They were rinsed with PBS, followed by the
various treatments (Fig. 1A, Supplementary Table S1; Sup-
plementary Data are available online at www.lie-
bertpub.com/scd). The recombinant proteins and reagents
used are the following: BMP4 (R&D 314-BP-010): 10 ng/mL;
SB-431542 (Sigma S4317): 20mM; SU5402 (Calbiochem
572630): 20mM; FGF2 (Peprotech): 4–20 ng/mL.
Real-time PCR and microarray-based gene
expression analyses
RNA was isolated using the RNeasy Mini Kit (Qiagen).
The cells were directly lyzed with a lysis buffer in the cell
culture wells, after rinsing with PBS. Total RNA from human
placenta (normal human placentas pooled from 15 Cauca-
sians, ages: 19–33) was purchased from Clontech (636527).
Reverse transcription was carried out using M-MLV re-
verse transcriptase (Promega) and Oligo-dT primer (Invitek).
Real-time PCR was carried out using SYBR Green mix (ABI)
with validated gene-specific primers (Supplementary Table
S2). The DDCt method was employed for calculations, em-
ploying the housekeeping genes (ACTB and GAPDH) for
normalization.
For microarray-based gene expression profiling, 500 ng
DNAse-free total RNA was biotin-labeled to generate cRNA,
employing a linear amplification kit (Ambion). The labeled
cRNA samples were hybridized onto HumanRef-8 v3 chips
following the manufacturer’s instructions (Illumina). Data
were analyzed using the software, Bead Studio, TIGR-MEV,
R (Bioconductor), MS Excel, MS Access, DAVID, and VENNY
interactive tool (Refer Supplementary Data).
Immunoblotting, immunostaining, and ELISA
Standard procedures were followed for immunoblotting
and immunostaining. Cells were rinsed with PBS before
performing these assays. For immunoblotting, cells were
scraped-off after adding the lysis buffer, and further lyses
were performed on ice to preserve the phosphorylation sta-
tus of the proteins. ELISA was carried out using the hCG
ELISA Kit (Bio-Quant, BQ 047F).
Transmission electron microscopy
Undifferentiated hESCs were cultured on Matrigel-coated
Thermanox plastic coverslips (Nunc; www.nuncbrand.com)
till they reached *50% confluency, and B/SB/SU treatment
was carried out for 5 days. Cells were then rinsed with PBS
and fixed with 2.5% glutaraldehyde in 50mM sodium ca-
codylate buffer (pH 7.4), supplemented with 50mM sodium
chloride for at least 30min at room temperature (refer Sup-
plementary Data).
Mitosis index
Cells were immunostained following standard procedures
to detect phosphorylated Histone H3 (H3p). The mitotic index
was computed as the ratio of H3p-positive nuclei to the total
number of nuclei [diamidino-2-phenylindoldihydrochloride-
positive (DAPI)]. The number of nuclei was determined using
the image processing software, ImageJ. At least 2,000 cells
were counted for each sample.
Fusion index
Cells were immunostained following standard procedures
to detect expression of E-cadherin (CDH1). For the estimation
of the fusion index, edges of the B/SB/SU-treated (5 days)
colonies were taken into consideration, as the bhCG-positive
cells were concentrated toward the edges (Figs. 3B and 4H,
Supplementary Fig. S3F). The fusion index was computed as
the number of nuclei (DAPI) in fused regions to the total
number of nuclei analyzed. The number of nuclei was deter-
mined using the image processing software, ImageJ. At least
600 nuclei were counted from 3 independent experiments.
Results
FGF inhibition, in addition to ACTIVIN/NODAL
inhibition, accelerates and accentuates
BMP4-mediated hESC differentiation, leading
to increased overlap with placental-regulated genes
BMP signaling promotes differentiation of hESCs into
multiple lineages [2,29,31,32], and ACTIVIN/NODAL and
FGF signaling can influence this lineage specification
[5,34,35]. Based on this evidence, we adopted a time-course
whole-genome expression profiling analysis to decipher the
influence of ACTIVIN/NODAL and FGF signaling on
BMP4-mediated differentiation of hESCs (Fig. 1A and Sup-
plementary Table S1). Pearson’s correlation coefficient (Fig.
1B, Supplementary Fig. S1A, Table S3), principal component
analysis (Fig. 1C, Supplementary Fig. S2), and the number of
differentially regulated genes (Fig. 1D) together revealed the
degree of segregation of each sample from the other, and
speed and extent of differentiation. BMP4-treated cells (B)
were the least differentiated (Fig. 1B–D, Supplementary Figs.
S1A and S2) and also shared the least overlap with placental-
regulated genes (genes regulated in placenta, in comparison
to hESCs) (Fig. 1G, Supplementary Table S4). The reason for
this could be the persistent pSMAD2 activity in these cells (B)
(Fig. 1E), which might have led to the higher expression of
NANOG and other pluripotency-supporting genes than all
the other treatments that involved ACTIVIN/NODAL inhi-
bition (B/SB, B/SB/F, and B/SB/SU) (Fig. 1F, Supplemen-
tary Fig. S1C). The overlap with placental-regulated genes
increased upon additional ACTIVIN/NODAL inhibition (B/
SB) (Fig. 1G, Supplementary Table S4), also showing in-
creased kinetics (Fig. 1C, Supplementary Fig. S2) and extent
of differentiation (Fig. 1D). When BMP activation and
ACTIVIN/NODAL inhibition were combined with FGF
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activation (B/SB/F), there was a reduction in the extent of
differentiation (Fig. 1C, D) and also, overlap with that of
placental-regulated genes (Fig. 1G, Supplementary Table S4).
ACTIVIN/NODAL and/or FGF signaling blocks TE differ-
entiation of hESCs induced by BMP4 [8,34,39], and this is in
corroboration with our data. In contrast, upon BMP activa-
tion, coupled with the inhibition of both ACTIVIN/NODAL
and FGF signaling (B/SB/SU), the transcriptome of these
cells segregated from the transcriptomes of cells treated with
other treatments (B, B/SB, and B/SB/F) in terms of maxi-
mum acceleration and extent of differentiation (Fig. 1B, D,
Supplementary Figs. S1A and S2). Furthermore, B/SB/SU-
treated cells acquired maximum overlap with the placental-
regulated genes (Fig. 1G, Supplementary Table S4). These
results suggest that additional inhibition of FGF signaling,
along with ACTIVIN/NODAL, leads to an increase in the
kinetics and extent of BMP4-mediated differentiation and
enhanced overlap with placental-regulated genes.
Additional inhibition of FGF signaling impairs
BMP4-driven differentiation into mesendoderm
and PE, but supports trophoblast induction
Transient upregulation of PS markers, T (Fig. 2A) and
EOMES (Fig. 2B), induction of epithelial-mesenchymal
transition (EMT) markers, VIM and SNAI2 (Fig. 2C), meso-
derm markers, PDGFRA and MESP1 (Fig. 2F), and endo-
derm markers, SOX17, CER1, GATA6, and SOX7 (Fig. 2D)
indicates that BMP4 treatment can support mesendoderm
and PE differentiation when the FGF pathway is not in-
hibited (B, BSB, and B/SB/F). ACTIVIN/NODAL plays an
important role in endodermal differentiation of hESCs [15],
and this explains the decreased expression of the endodermal
markers, SOX17 and CER1, upon its inhibition (B/SB, B/SB/
F, and B/SB/SU) (Fig. 2D). However, the expression of PE
markers, GATA6 and SOX7, still remained high upon B/SB
and B/SB/F treatments, but diminished (GATA6:*3–10-fold
FIG. 1. Experimental design and BMP4-induced differentiation are accelerated and accentuated with additional inhibition
of ACTIVIN/NODAL and FGF signaling. (A) Details of treatments [BMP4 (B): 10 ng/mL; SB431542 (SB): 20mM; SU5402 (SU):
20 mM; FGF2 (F): 20 ng/mL] [Hour (H); Day (D)]. (B) Dendrogram based on Pearson’s correlation coefficient between samples
(5 days). (C) Principal Component Analysis on the regulated genes (2-fold), with respect to their expression in hESCs in at
least one of the indicated (5 days). (D) Number of significantly regulated genes after 5 days of the indicated treatments, with
respect to hESCs. Blue, downregulated; red, upregulated. (E)Western blot analysis for the indicated proteins and samples. (F)
Heat map depicting the regulation of genes with respect to hESCs in the indicated samples. (G) Percentage overlaps of
regulated genes (2-fold) in each sample (5 days) with respect to hESCs, with placental-regulated genes. BMP, bone mor-
phogenetic protein; hESCs, human embryonic stem cells. Color images available online at www.liebertpub.com/scd
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lower and SOX7: *8–12-fold lower) with FGF inhibition
(B/SB/SU) (Fig. 2D, F). Although FGF signaling is required
for PE induction in mice [19], it has been shown not to be
required for human PE induction [40]. However, the re-
duction in expression of PE markers upon B/SB/SU treat-
ment could be a combinatorial effect. On the other hand, B/
SB/SU treatment led to the induction of the epithelial
marker, E-Cadherin (CDH1), and did not support induction
of the mesenchymal marker, Vimentin (VIM), and the me-
sodermal, endodermal, or neuroectodermal markers (Fig.
2C–F). The data also revealed that none of the treatments
(B, BSB, B/SB/F, and B/SB/SU) supported neuroecto-
dermal differentiation (Fig. 2E, F). BMP activation is known
to block neuroectodermal differentiation [5,26,27,35,41].
Although a number of trophoblast-related genes were in-
duced upon all treatments (H19, GATA2, and GATA3), the
degree of induction of trophoblast-related genes, such as
CGB, CGB1, CGB5, KRT7, GCM1, and CYP19A1, was much
higher in B/SB/SU-treated cells, compared to the others (B,
B/SB, and B/SB/F) (Fig. 2E, F, Supplementary Table S5).
However, B/SB/SU treatment led to the induction of only
trophoblast markers, but not any other lineage markers
analyzed (Fig. 2E, F).
Taken together, our results illustrate that BMP signaling,
irrespective of the presence or absence of ACTIVIN/NODAL
signaling and in the presence of FGF signaling (B, B/SB, and
B/SB/F), can support both mesendoderm and PE differen-
tiation. However, inhibition of both ACTIVIN/NODAL and
FGF signaling in conjunction with BMP activation (B/SB/
SU) affects PE induction and supports neither mesendoderm
nor neuroectoderm induction, but however supports tro-
phoblast induction of hESCs.
BMP activation, in conjunction with the inhibition
of ACTIVIN/NODAL and FGF signaling (B/SB/SU),
leads to differentiation of hESCs to bhCG-secreting
syncytiotrophoblast, with relatively compromised
CDX2 expression, and does not support
the formation of extravillous trophoblast
Trophoblast stem (TS) cells can adopt 2 mutually exclu-
sive differentiation paths, either the noninvasive villous
FIG. 2. FGF and ACTIVIN/NODAL inhibition prevents BMP4-driven differentiation into mesendoderm and PE and
specifically supports trophoblast induction. (A) Real-time PCR based analysis of T expression in the indicated samples. (B)
Analysis of of EOMES expression in the indicated samples. (C) Analysis of CDH1, SNAI2 and VIM expression in the indicated
samples (5 days). (D) Analysis of GATA6, SOX7, SOX17, and CER1 expression in the indicated samples. (E) Analysis of the
indicated genes in B/SB/SU-treated samples (5 days). (F) Heat map depicting the regulation of genes with respect to hESCs
in the indicated samples. PE, primitive endoderm. Color images available online at www.liebertpub.com/scd
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syncytiotrophoblast that remains epithelial or invasive ex-
travillous cytotrophoblasts that undergo EMT [42]. The 2
trophoblast cell types are distinguishable from each other by
the expression of specific markers [43–47]. ELISA-based re-
sults strongly indicated hCG secretion by cells in which both
the self-renewal supporting pathways were blocked, along
with BMP activation (B/SB/SU), whereas no secretion was
detected as a consequence of the other treatments in a span
of 5 days (B, B/SB, and B/SB/F) (Fig. 3A). Both mRNA
(CGB) and protein levels revealed a high proportion of syn-
cytiotrophoblast-specific bhCG-expressing cells among the
B/SB/SU-treated cells (Figs. 3B, D and 4H, Supplementary
Fig. S3A). The induction of CGB at such high levels was
reproducible (Fig. S3B). The pattern of bhCG expression re-
flects that the differentiation proceeded from edges of the
colonies toward inside (Figs. 3B and 4H, Supplementary Fig.
S3A). Even phenotypically, the colony edges of the B/SB/
SU-treated colonies looked prominently different from the
inner region, unlike the other treatments (Supplementary
Fig. S5). The B/SB/SU-treated cells also expressed the gen-
eral marker of the trophoblast lineage KRT7 [47] with more
intense expression toward edges of the colonies (Fig. 3C). In
addition, the expression of the extravillous trophoblast
marker HLA-G (Fig. 3E, Supplementary Fig. S3C) was highly
compromised upon B/SB/SU treatment. However, the dif-
ference in HLA-G levels was only seen at the protein level
and not at the mRNA level that could be due to probable
post-transcriptional regulation and requires further investi-
gation. In addition, the epithelial marker E-CADHERIN
(CDH1) was induced both at the mRNA and protein levels in
the B/SB/SU-treated cells, while the mesenchymal markers,
SNAI2 and VIMENTIN, were downregulated (Figs. 2C and
3F). The other treatments (B, B/SB, and B/SB/F) resulted in
high induction of both SNAI2 and VIM and downregulation
of CDH1 expression (Fig. 2C).
Silencing of OCT4, SOX2, or NANOG in hESCs supports
trophoblast differentiation [48–50], and the ability of OCT4
to silence hCGa and hCGb gene expression has been de-
scribed [51]. Systematic loss of expression of the pluripotency
markers, such as OCT4, SOX2, and NANOG, coincided with
FIG. 3. B/SB/SU treatment transiently upregulates CDX2 and induces differentiation to bhCG-secreting syncytiotrophoblast
and does not support extravillous trophoblast formation. (A) ELISA-mediated estimation of hCG concentration in growth
media in the indicated samples. (B) Representative immunostain for bhCG expression in B/SB/SU-treated cells. (C) Re-
presentative immunostain for KRT7 expression in B/SB/SU-treated cells. (D) Analysis of OCT4, NANOG, and CGB expression
in the indicated samples. (E) Western blot analysis of HLA-G expression in the indicated samples. (F) Representative im-
munostains for E-Cadherin (CDH1) and Vimentin (VIM) expression in B/SB/SU-treated cells. (G) Analysis of OCT4, SOX2,
NANOG, and CGB, during B/SB/SU treatment. (H) Analysis of CDX2 expression in the indicated samples. (I) Western blot
analysis of CDX2 expression in the indicated samples (5 days). Color images available online at www.liebertpub.com/scd
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the induction of the syncytiotrophoblast marker CGB (Fig.
3G). The reduction in the pluripotency-associated markers
was observed as a result of all the treatments (B, B/SB, B/
SB/F, and B/SB/SU) (Figs. 1F, 3D, 3G). The TE marker
CDX2 was induced by all the treatments (B, B/SB, B/SB/F,
and B/SB/SU) (Fig. 3H). The treatments involving ACTI-
VIN/NODAL inhibition (B/SB and B/SB/SU) led to a
transient induction of CDX2, whereas the treatment involv-
ing FGF stimulation (B/SB/F) led to its sustained induction.
At the protein level, CDX2 expression was relatively the
lowest in B/SB/SU-treated cells (Fig. 3I). CDX2 expression
depends on an FGF4-induced MEK-ERK pathway in mouse
TS cells [52], and upon FGF4 withdrawal [53], TS cells dif-
ferentiate, preferential to spongiotrophoblast and syncytio-
trophoblast [54]. Taken together, our results present strong
evidence that BMP activation, coupled with ACTIVIN/
NODAL and FGF inhibition, results in a transient induction
of CDX2, leading to differentiation of hESCs to epithelial,
bhCG-secreting syncytiotrophoblast, thus evading extra-
villous trophoblast induction.
BMP activation, in conjunction with inhibition
of ACTIVIN/NODAL and FGF signaling
(B/SB/SU), induces cell fusion
Our microarray data revealed coregulation of several
syncytiotrophoblast-expressed genes with those coding for
bhCG (CGB, CGB1, CGB5, and CGB7) (Fig. 4A, Supplemen-
tary Fig. S3D). They include the genes involved in estrogen/
progesterone biosynthesis and metabolism (HSD17B1,
HSD3B1, CYP19A1, and CYP11A1) [55], the tumor suppres-
sor HOP (NECC1) [56], CYP19A1 (aromatase), and fusogens
FIG. 4. B/SB/SU treatment induces the expression of fusogens and differentiation to multinucleated syncytiotrophoblast.
(A) Heat map and expression profile of coregulated and induced genes in comparison to hESCs during the B/SB/SU
treatment. (B) Real-time PCR-based expression analysis of the indicated genes during B/SB/SU treatment. (C) Representative
immunostain for E- Cadherin (CDH1) expression in the indicated samples. (D) Representative immunostain for CDH1 in the
B/SB/SU-treated samples (5 days), exhibiting multinucleated regions in the colony edges and fusion indices of 3 different
experiments. CDH1, green; DAPI, blue. (E) Representative immunostain for ß-Actin (ACTB) in the B/SB/SU-treated samples
(5 days), exhibiting multinucleated regions in the colony edges. ACTB: yellow; DAPI: blue. (F) Representative electron mi-
croscopy images depicting multinucleated cells in B/SB/SU-treated samples (5 days). Scale bar: 5 mm. (G) Mitotic index for
the indicated samples. (H) Representative immunostains for bhCG (green) and SYNCYTIN1 (red) expression in B/SB/SU-
treated cells. DAPI, diamidino-2-phenylindoldihydrochloride. Color images available online at www.liebertpub.com/scd
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[GCM1 and Syncytins (ERVWE1 and HERV-FRD)] [57–59].
Although fusogens and HOP were induced by the other
treatments (B, B/SB, and B/SB/F), the induction was much
higher (*200–300-fold) with the B/SB/SU treatment (Fig.
4A, B, Supplementary Fig. S3E). In addition, SYNCYTIN 1
(ERVWE1) was seen to be expressed (Fig. 4C, H). The cellular
regions positive for b-hCG exhibited the presence of clus-
tered nuclei that were mostly concentrated toward the edges
of the colony (Figs. 3B and 4H, Supplementary Fig. S3A, F).
A closer examination of the E-CADHERIN- or ß-Actin-
stained colony edges led us to discover that several multi-
nucleated regions were present in these regions (Fig. 4C–E,
Supplementary Fig. S4A). The fusion index ranged
*60%–80% (Fig. 4D). Furthermore, electron microscopy
analysis also confirmed the presence of multinucleated cells
among the B/SB/SU-treated cell population (Fig. 4F). In
addition, several genes and pathways functional in human
placenta, such as PPAR signaling, xenobiotic, and fatty acid
metabolisms, were also active after B/SB/SU treatment
(Supplementary Fig. S4B). Taken together, our data re-
emphasize that BMP activation, in conjunction with inhibi-
tion of ACTIVIN/NODAL and FGF signaling, leads hESC
differentiation to cell fusion mediated-bhCG-secreting syn-
cytiotrophoblast formation.
Pathway analyses also revealed the regulation of the cell
cycle and p53 pathways in the B/SB/SU-treated cells (Sup-
plementary Fig. S4B). Cell cycle disruption [60] as well as cell
fusion are involved in the formation of syncytiotrophoblast,
which is nonproliferative and considered to represent a mi-
totically end-stage cell [61,62]. Induction of the CDK/CY-
CLIN inhibitors (GADD45G, p21, and p57), downregulation
of mitotic genes (CDK1, CCNA1, CCNA2, CCNB1, and
CCNB2) (Supplementary Fig. S4C, Table S6), and a reduction
in mitotic index, based on histone H3 phosphorylation (H3p)
(Fig. 4G, Supplementary Fig. S4D), suggest that cell cycle
was affected in the B/SB/SU-treated cells. H3p is a down-
stream marker for chromosome condensation and entry into
mitosis [63], and its expression is regulated by the ERK/
MAPK pathway (Chambard). Cell division is affected in
dominant negative FGF receptor mouse embryos, though
there is no increase in cell death [13]. The DNA damage-
driven apoptosis-inducing factors CHEK1, CHEK2, and TP53
[64] were seen to be downregulated in B/SB/SU-treated cells
(Supplementary Fig. S4D, Table S6), during which the TP53
inhibitor MDM2 [65] was induced. Both the apoptotic (BAD)
and antiapoptotic (BCL-2 and BCL2L1) BCL-2 family mem-
bers were upregulated after B/SB/SU treatment (Supple-
mentary Fig. S4D, Table S6). BCL-2 protein is expressed in
syncytiotrophoblast and syncytial knots, thus suggesting
their involvement in protection from apoptosis [66]. Thus,
our results indicate that the differentiation of hESCs to syn-
cytiotrophoblast, mediated by B/SB/SU treatment, is
brought about via the induction of fusogens and involves cell
cycle exit.
Autocrine signaling leads to abrogation of BMP
signaling and WNT activation when hESCs
differentiate to syncytiotrophoblast
Although all treatments involved the activation of BMP
signaling, only the B/SB/SU-treated cells had a reduction
in pSMAD1 (phosphorylated SMAD1) after 5 days
(Fig. 5A). This was unexpected as the cells were treated
with a fresh medium, along with the respective treatments
every day. The reduction in pSMAD1 levels in the B/SB/
SU-treated samples coincided with the induction of the
BMP-signaling antagonists, Gremlin2 (GREM2) and Chor-
din (CHRD) (Fig. 5B, C), and increased phosphorylation of
GSK3b (Fig. 5D). The phosphorylation of the SMAD1 pro-
tein at the linker region by GSK3b causes degradation of
SMAD1 (reviewed in [67]). The increased phosphorylation
of GSK3b also indicates the activation of WNT signaling.
The WNT antagonist Dickkopf homolog 1 (DKK1) was not
induced upon B/SB/SU treatment, whereas when FGF
signaling was kept active (B/SB/F), it was induced
(Fig. 5E). The reduction in pSMAD1, along with the in-
duction of GREM2 and CHRD, indicates a decrease in BMP
signaling, and the increased phosphorylation of GSK3b,
along with diminished DKK1 levels, indicates activation of
WNT signaling. These events coincided with the activation
of syncytiotrophoblast genes and bhCG-secretion (5 days of
B/SB/SU treatment) (Figs. 2F, 3A–C, and 4A, Supplemen-
tary Fig. S4A). A recent finding has shown the importance
of WNT signaling for the fusion inducing-GCM1/syncytin
pathway in human choriocarcinoma cells [68]. Taken together,
our data indicate that although trophoblast induction requires
BMP activation, it is affected via autocrine signaling during
subsequent differentiation to syncytiotrophoblast, when WNT
signaling is active.
Inhibition of the FGF pathway supports
differentiation of hESCs to hCG-secreting
syncytiotrophoblast, and additional BMP
activation and ACTIVIN/NODAL inhibition
accelerate as well as specify the differentiation
toward syncytiotrophoblast
Our results revealed that all the treatments (B, B/SB, and
B/SB/F), except the one involving FGF inhibition (B/SB/
SU), support mesendoderm induction (Fig. 2). Although all
the treatments led to the induction of CGB, bhCG secretion
was detected only upon B/SB/SU treatment, indicative of
syncytiotrophoblast formation (Figs. 3A, B, D and 4H) that
involved additional FGF inhibition. From this, we hypothe-
sized that the additional blocking of FGF signaling might be
responsible for the diversion of hESCs to a syncytrophoblast
lineage and hCG secretion, preventing mesendoderm and
neuroectoderm induction. To confirm this, we investigated
the effect of FGF inhibition on syncytiotrophoblast induction
of hESCs, using the FGF inhibitor SU5402 (SU) (Supple-
mentary Table S1).
ELISA results revealed hCG secretion upon FGF inhibition
alone (SU) or when coupled with BMP activation (B/SU)
or ACTIVIN/NODAL inhibition (SB/SU) (Fig. 6A). CGB
was induced upon FGF inhibition (Fig. 6B, D, J, Supple-
mentary Fig. S6B, D). The pluripotency-associated genes,
such as OCT4, SOX2, and NANOG, were downregulated as
a result of FGF inhibition (SU) (Fig. 6B, J, Supplementary
Fig. S6E).
Similar to the B/SB/SU-treatment, after 5 days, FGF in-
hibition (SU) led to the induction of the epithelial marker,
CDH1, the trophoblast markers, such as ID2 and IPL, and also
the syncytiotrophoblast genes, such as the bhCG-encoding
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genes (CGB, CGB1, and CGB5), the fusogens (GCM1 and
Syncytins), aromatase (CYP19A1), and HOPX (Supplemen-
tary Fig. S1B, Figs. 3D, 4A, and 6B, D, J, Supplementary Fig.
S6B). At the protein level, the SU-treated cells expressed E-
CADHERIN (CDH1), SYNCYTIN1 (ERVWE1), bhCG, and
KRT7 (Fig. 6F–H). The expression of SYNCYTIN1 was rather
weak (Fig. 6G). Unlike the B/SB/SU-treated cells that ex-
hibited very high proportion of bhCG-positive cells toward
the colony edges, also having marked morphological de-
marcation from the inner areas, bhCG-positive cells were
haphazardly distributed among the SU-treated colonies with
no demarcating morphology of the edges (Figs. 3B, 4H, and
6G, Supplementary Figs. S4 and S6J). The expression profile
of the extraembryonic endoderm marker GATA6 was quite
similar to that of the B/SB/SU-treated samples (Fig. S6F). In
addition, SOX7 was induced upon FGF inhibition (Fig. S6G),
but both these genes were expressed at much lower levels
(GATA6: *3–10-fold lower and SOX7: *8–12-fold lower)
than that of all the other treatments (B, B/SB, and B/SB/F)
(Supplementary Fig. S6F, G, Fig. 2D). CDX2 was transiently
induced upon FGF inhibition (SU), similar to the conse-
quence of B/SB/SU treatment, reflecting further differenti-
ation of the cells, leaving the TS cell status (Figs. 3H, I and
6D, E, Supplementary Fig. S6H). Also, similar to the B/SB/
SU-treated cells, the expression of the extravillous tropho-
blast marker HLA-G was relatively lower than that of the
B/SB/F-treated cells that had FGF signalling activated, in-
dicating its possible role in extravillous trophoblast induc-
tion (Fig. 6E). Principal Component Analysis of the global
time-course transcription profiles revealed that both the
B/SB/SU- and SU-treated cells followed a similar pattern of
differentiation, but seemed to be less differentiated than the
B/SB/SU-treated cells (Fig. 6C, Supplementary Fig. S6I). The
expression pattern of some of the analyzed cell cycle-related
genes, upon FGF inhibition (SU), was similar to that seen in
B/SB/SU-treated cells, and also a reduction in the mitotic
index showed compromise of cell cycle as a result of FGF
inhibition (Fig. S6K, L). These results suggest that inhibition
of FGF could be the key to differentiating hESCs to the
syncytiotrophoblast lineage.
In spite of many similarities, morphological analysis
during the course of treatments and the transcriptome
changes revealed that the B/SB/SU treatment induced a
more robust and faster differentiation than the SU treatment
(Supplementary Fig. S6J, Fig. 6C, Supplementary Fig. S6I).
Global transcriptional profiles revealed that the B/SB/SU-
and SU-treated cells correlated more with each other than
with the other cells after 5 days of treatment (B, B/SB, and
B/SB/F) (Fig. 6C, Supplementary Fig. S6A, I). The B/SB/
SU-treated cells had a higher overlap of the regulated
genes, with that of the placental-regulated genes, than the
SU-treated cells (Fig. 6I). The expression levels of the bhCG-
encoding genes (CGB, CGB1, CGB, and CGB7) were higher
than that of the SU-treated cells (Fig. 6D, Supplementary
Fig. S6C).
Taken together, our results show that the inhibition of the
FGF pathway (SU) supports differentiation of hESCs to hCG-
secreting syncytiotrophoblast, acting as a key to syncytio-
trophoblast induction of hESCs. When FGF inhibition is
coupled with BMP activation and ACTIVIN/NODAL inhi-
bition (B/SB/SU), it leads to a more robust differentiation of
hESCs, specifically into syncytiotrophoblast.
FIG. 5. Autocrine signaling leads to the abrogation of BMP signaling and WNT activation in B/SB/SU-treated cells (5
days). (A) Western blot analysis for the indicated proteins and samples. The 3-day (3D) samples were not considered for
analysis due to unequal loading. (B) Expression analysis of GREM2 in the indicated samples. (C) Expression analysis of
CHRD, FST, and GREM2 in the indicated samples. (D)Western blot analysis for the indicated proteins in B/SB/SU-treated
samples. (E) Expression analysis of DKK1 in the indicated samples. GREM2, Gremlin2; CHRD, Chordin; DKK1, dickkopf
homolog 1. Color images available online at www.liebertpub.com/scd
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Discussion
Activation of BMP signaling has the potential to direct
hESCs to both the embryonic mesoderm lineage [29–31] and
extraembryonic lineages, such as PE and trophoblast
[2,20,32]. The BMP-driven differentiation potential of these
cells can be restricted to specific lineages from the broad
range of choices, based on the activity and influence of other
pathways, such as ACTIVIN/NODAL and FGF signaling
[5,34,35]. With this prior knowledge, we set out to decipher
the influence of these pathways on BMP4-mediated lineage
decisions imposed on hESCs.
All our treatments involved BMP activation, which is
known to have an inhibitory capability on neuroectodermal
differentiation, and therefore this lineage induction was
averted (Fig. 2E, F) in spite of ACTIVIN/NODAL inhibition
that supports neuroectodermal induction [5,7,26–28]. When
the ACTIVIN/NODAL pathway is blocked, while both BMP
and FGF pathways are active, mesendoderm induction is
inhibited [20]. Our results revealed induction of mesoderm
markers, such as PDGFRA, NKX3-1, and NKX2-5, upon BMP
activation and ACTIVIN/NODAL inhibition (B/SB) and
upon additional FGF activation (B/SB/F), respectively (Fig.
2F). It could be possible that even if ACTIVIN/NODAL in-
hibition can grossly affect mesendoderm differentiation, it
might have a positive effect on certain mesoderm sub-
lineages at this particular BMP4 concentration (10 ng/ml).
This however requires further investigation.
Our results revealed that when BMP activation and
ACTIVIN/NODAL inhibition were coupled with FGF in-
hibition (B/SB/SU), both the PS markers, T and EOMES,
were highly downregulated, and none of the mesendoderm
markers investigated were upregulated (Fig. 2). FGF inhi-
bition is known to oppose neural and mesendodermal
FIG. 6. FGF inhibition in hESC supports differentiation to hCG-secreting syncytiotrophoblast. (A) ELISA-based estimation
of hCG concentration in the growth medium after the indicated treatments. (B) Expression analysis of indicated genes in SU-
treated samples (5 days). (C) Principal Component Analysis of regulated genes (2-fold) in the indicated samples. (D) Ex-
pression of CDX2, bhCG-encoding genes (CGB, CGB1, and CGB5), and HERV-FRD in the indicated samples, in comparison to
hESCs (microarray data). (E) Western blot analysis for the expression of the indicated proteins and samples. (F) Re-
presentative immunostain for E-Cadherin (CDH1) expression in SU-treated cells. (G) Representative immunostain for
SYNCYTIN1 (ERVWE1) and bhCG expression in SU-treated cells. (H) Representative immunostain for KRT7 expression in
SU-treated cells. (I) Venn diagrams representing the overlap of the up- or downregulated genes between the indicated
samples (5 days), in comparison to hESCs. ( J) Heat map depicting the regulation of genes with respect to hESCs in the
indicated samples. Color images available online at www.liebertpub.com/scd
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induction [12,13,20,69]. FGF signaling has a role in switch-
ing the outcome of BMP4-driven differentiation of hESCs to
the mesendoderm via the maintenance of NANOG [20]. Our
results also show continuous downregulation of NANOG
upon B/SB/SU treatment (Fig. 3G, Supplementary Fig.
S1C). Along with this, considering the downregulation of
PS markers and noninduction of mesoderm markers, it can
be concluded that B/SB/SU treatment circumvents meso-
derm induction (Fig. 2). Excessive FGF activation promotes
PE formation, and FGF inhibition causes failure of PE
formation in mice [19], but it has been shown not to be
required for human PE induction [40]. Our results show
that the expression of both the PE markers, GATA6 and
SOX7, was affected upon FGF inhibition (Fig. 2D), and
also, the treatments involving FGF inhibition (SU and
B/SB/SU) led to a similar expression pattern of GATA6
(Supplementary Fig. S6F). As our data show a significant
reduction in the induction of PE markers upon FGF inhi-
bition (SU and B/SB/SU), it could be possible that al-
though FGF inhibition cannot solely prevent PE induction
from hESCs, its inhibition might contribute to this, in
combination with other factors, such as ACTIVIN/NODAL
inhibition. This requires further investigation. Taken to-
gether, FGF signaling has an important role in switching
the outcome of BMP4-driven differentiation not only to
mesendoderm but also to PE.
Other than mesoderm and PE, BMP signaling can lead to
trophoblast induction (Xu et al.; Das et al.). All our experi-
ments were conducted under defined culture conditions, in
contrast to other studies on BMP-induced differentiation of
hESCs to trophoblast that were conducted in an MEF-con-
ditioned medium that could be a source of many growth
factors, such as FGF (Xu et al.; Das et al.). Our results show
that upon inhibition of both ACTIVIN/NODAL and FGF
pathways, along with BMP activation (B/SB/SU), hESCs
differentiate toward syncytiotrophoblast and lacked extra-
villous trophoblast characteristics (Figs. 3 and 4, Supple-
mentary Figs. S3 and S4).
FGF and ACTIVIN/NODAL signaling has a conserved
role in TS cell maintenance [53,70], and the FGF-responsive
transcription factors, Eomes and CDX2, are crucial for TE
development [71]. FGF4 withdrawal or MEKK4 inactivation
in TS cells induces differentiation, accompanied by the
downregulation of these factors [53]. Our results reveal
transient induction of CDX2, when FGF signaling was either
exogenously blocked (B/SB/SU and SU) or not blocked (B/
SB), but persistent induction with continuous FGF activation
(B/SB/F) (Figs. 3H, I and 6D, E, Supplementary Fig. S6H).
FIG. 7. A model summarizing the outcome of B/SB/SU treatment of hESCs that leads to syncytiotrophoblast induction
(‘‘ + ’’ and ‘‘ - ’’ represent activation and inhibition, respectively). FGF inhibition (SU) supports syncytiotrophoblast induction,
but to a lesser extent compared to B/SB/SU treatment. The pathway–lineage map, prepared on the basis of our findings and
that of other laboratories, represents the consolidated outcome of BMP4 activation and inhibition of both ACTIVIN/NODAL
and FGF pathways (B/SB/SU). Dotted lines: the reason for the inhibition of PE induction from hESCs upon B/SB/SU
treatment could be a combinatorial effect of inhibition of both ACTIVIN/NODAL and FGF, but this requires further
investigation. Color images available online at www.liebertpub.com/scd
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However, EOMES was persistently downregulated upon B/
SB/SU treatment (Fig. 2B). Similar observations in the ex-
pression patterns of both CDX2 and EOMES upon ACTI-
VIN/NODAL inhibition have been reported [39]. In spite of
the dependence of CDX2 expression on an FGF4-induced
MEK-ERK pathway in mouse TS cells [52], its inhibition in
mouse embryos caused neither an alteration in the TE cell
fate nor a loss of CDX2 expression [19]. Hence, our results
suggest that upon BMP induction, CDX2 is induced even in
the absence of FGF signaling and is downregulated upon
further differentiation to syncytiotrophoblast (Figs. 3H, I and
6D, E, Supplementary Fig. S6H). Although the possibility of
the requirement of EOMES in the extravillous trophoblast
differentiation cannot be ruled out, our results suggest the
possibility of it not being required for the differentiation of
hESCs into syncytiotrophoblast.
Syncytiotrophoblast is the nonproliferative layer of the
placenta, which is formed by continuous fusion of cyto-
trophoblasts, and is thought to represent a mitotically end
stage [61,62]. Although FGF signaling is required for the
proliferation and growth of extraembryonic ectoderm, its
absence neither affects its formation nor increases apoptosis
[13], and this is in corroboration with our findings. Our
further study of the B/SB/SU-induced differentiation to
syncytiotrophoblast revealed a reduction in the mitotic in-
dex, and also, transcriptome analysis revealed regulation of
cell cycle-related genes, favoring exit of the cell cycle (Fig.
4G, Supplementary Fig. S4B–D). However, this was accom-
panied by the induction of both apoptotic and antiapoptotic
factors, such as the BCL2 family and the p53-MDM2 path-
way. BCL2 is expressed in syncytiotrophoblast and syncytial
knots, suggesting protection from apoptosis [66], and the
importance of the p53-Mdm2 pathway in the development of
trophoblast and its lineages has been reported [72]. Hence,
our results demonstrate that syncytiotrophoblast formation
involves cell cycle exit.
Another feature in the B/SB/SU-treated cells was that in
spite of BMP signaling, a reduction in pSMAD1 was ob-
served after 5 days when the syncytiotrophoblast character-
istics were evident. This coincided with the enhanced
expression of pGSK3b and the WNT antagonist, DKK1 (Fig.
5), reflecting WNT activation, which has been shown to be
important for the GCM1/syncytin pathway in human cho-
riocarcinoma cells, leading to syncytiotrophoblast formation
[68]. Phosphorylation of GSK3b can induce degradation of
SMAD1 protein through phosphorylation of its linker region
[67]. Our results clearly indicate that though BMP signaling
initially supports the differentiation of hESCs to trophoblast,
BMP signaling is negatively modulated during further dif-
ferentiation to syncytiotrophoblast.
As B/SB/SU treatment specifically supported differen-
tiation of hESCs to syncytiotrophoblast and not mesendo-
derm, extravillous trophoblast and PE, unlike all the other
treatments (B, B/SB, and B/SB/F), we hypothesized that
FGF inhibition might be causing this specific lineage com-
mitment. Our findings reveal that inhibition of FGF sig-
naling alone in hESCs supports their differentiation to
syncytiotrophoblast, also exhibiting a reduction in the mi-
totic index (Fig. 6, Supplementary Fig. S6). FGF signaling is
essential for cell cycle progression [73], and Mekk4 inacti-
vation in TS cells lead to differentiation, preferential to
spongiotrophoblast and syncytiotrophoblast [54]. The cou-
pling of FGF inhibition with BMP activation and ACTI-
VIN/NODAL inhibition led to syncytiotrophoblast
induction, with a greater overlap with placental-regulated
genes and prevention of mesendoderm, neuroectoderm,
extravillous trophoblast, and PE induction (Figs. 2–4 and
6I). In fact, FGF inhibition alone (SU), or in combination
with either BMP activation or ACTIVIN/NODAL inhibi-
tion (B/SU and SB/SU), also led to CGB induction and hCG
hormone secretion, a characteristic feature of syncytio-
trophoblasts (Figs. 3A, B, D, J and 6A, B, Supplementary
Fig. S6B, D). Further, the SU-treated cells expressed E-
CADHERIN, SYNCYTIN1, bhCG, and KRT7 (Fig. 6F–H).
Taken together, the findings from our study strongly em-
phasize that FGF inhibition acts as a key in supporting
syncytiotrophoblast differentiation of hESCs, thus pre-
venting BMP-mediated differentiation to mesoderm, extra-
villous trophoblast, and PE (Fig. 7). Also, BMP signaling in
conjunction with inhibition of both ACTIVIN/NODAL and
FGF signaling specifically drives hESCs toward syncytio-
trophoblast, preventing differentiation toward mesendo-
derm, neuroectoderm, extravillous trophoblast, and PE
(Fig. 7).
We believe that this study provides valuable information
for directed in vitro differentiation of hESCs. Furthermore,
the data from this study can also be used in understanding
the dynamics of gene regulation during syncytiotrophoblast
formation that could be useful in understanding placental
disorders, such as pre-eclampsia.
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